Bio

Mr. Burns is a Vice President of Equity Research at H.C. Wainwright whose research focuses on the biotechnology sector. Mr. Burns’ expertise spans the universe of next-generation approaches to the treatment of cancer, with particular focus on the immuno-oncology and precision oncology sectors. Prior to joining H.C. Wainwright, Mr. Burns worked at BMO Capital Markets as an equity research associate covering Major Pharma under analyst Alex Arfaei; he followed multiple Top 10 pharmaceutical firms and focused on tracking developments in the oncology arena, particularly within the context of checkpoint inhibition and immunotherapy. Mr. Burns’ educational background includes a Master’s degree in Medical Science from Boston University School of Medicine as well as a Bachelor’s degree in Chemistry from Brooklyn College. Mr. Burns also attended Boston University School of Medicine as a medical student for three years.